Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  2. JUNS

(JUNS)

NCM – Real Time Price. Currency in USD

0.35

+0.00 (0.29%)

At close: Mar 27, 2026, 4:00 PM EDT

0.40

+0.05 (14.29%)

After-hours: Mar 27, 2026, 7:49 PM EDT

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile

Jupiter Neurosciences, Inc.

CountryUnited States
IndustryBiotechnology
SectorHealthcare
IPO Date2024-12-03
CEOChrister Rosen

About the company

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer’s disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson’s disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson’s disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.

Key Executives

NamePosition
Dr. Claes Wahlestedt M.D., Ph.D.Co-Founder, Co-Chairman of Scientific Advisory Board & Consulting Chief Medical Officer
Dr. Marshall Hayward Ph.D.Co-Founder, Chief Scientific Officer & Director
Dr. Shaun P. Brothers Ph.D.Co-Founder Member of Scientific Advisory Board & Consulting Vice President of Science Research
Mr. Alexander RosenCo-Founder & Chief Administrative Officer
Mr. Christer RosenCo-Founder, CEO & Chairman of the Board
Mr. Saleem Elmasri CPACFO & Secretary
Ms. Alison D. Silva MA, MSPresident, Chief Business Officer & Director

Jupiter Neurosciences, Inc.

CountryUnited States
IndustryBiotechnology
SectorHealthcare
IPO Date2024-12-03
CEOChrister Rosen

Contact Details

Address:1001 North US Highway 1, Suite 504, Jupiter, Florida 33477, United States
Phone:561 406 6154
Website:https://jupiterneurosciences.c...

Stock Details

Ticker Symbol:JUNS
Exchange:NASDAQ
Fiscal Year:January - December
Reporting Currency:USD
CIK Code:1679628
ISIN Number:US48208B2034
Employer ID:47-4828381
SIC Code:2834

Latest SEC Filings

DateTypeDocument
2025-12-238-Kform8-k.htm
2025-12-228-Kform8-k.htm
2025-11-26S-1forms-1.htm
2025-11-208-K/Aform8-ka.htm
2025-11-1410-Qform10-q.htm
2025-11-07DEFA14Aformdefa14a.htm
2025-11-06DEFA14Aformdefa14a.htm
2025-10-28PRER14Aformprer14a.htm
2025-10-278-Kform8-k.htm
2025-10-17PRE 14Aformpre14a.htm